Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • Harvard Bioscience's Cash from Financing Activities fell 16074.14% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 7636.68%. This contributed to the annual value of -$131000.0 for FY2024, which is 9892.04% up from last year.
  • Per Harvard Bioscience's latest filing, its Cash from Financing Activities stood at -$1.3 million for Q3 2025, which was down 16074.14% from -$1.3 million recorded in Q2 2025.
  • Harvard Bioscience's Cash from Financing Activities' 5-year high stood at $2.6 million during Q4 2021, with a 5-year trough of -$4.1 million in Q4 2023.
  • In the last 5 years, Harvard Bioscience's Cash from Financing Activities had a median value of -$1.2 million in 2025 and averaged -$1.0 million.
  • As far as peak fluctuations go, Harvard Bioscience's Cash from Financing Activities plummeted by 317765.96% in 2023, and later surged by 17650.91% in 2024.
  • Harvard Bioscience's Cash from Financing Activities (Quarter) stood at $2.6 million in 2021, then plummeted by 205.24% to -$2.7 million in 2022, then crashed by 50.77% to -$4.1 million in 2023, then soared by 67.03% to -$1.4 million in 2024, then increased by 5.82% to -$1.3 million in 2025.
  • Its Cash from Financing Activities stands at -$1.3 million for Q3 2025, versus -$1.3 million for Q2 2025 and -$1.2 million for Q1 2025.